fontolizumab

mAbexperimental

Fontolizumab is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint. — Wikipedia

Clinical trial activity

2 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2005 (NCT00281294)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • asn100
  • fontolizumab
  • fontolizumab
  • fontolizumab
  • huzaf

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02940626Phase 2Nov 1, 2016Arsanis, Inc.
NCT00281294Phase 2Dec 1, 2005Altoona Center for Clinical Research, Coeur d Alene Arthritis Clinic, Denver Arthritis Clinic, Michigan State University, PDL BioPharma, Stanford University, Virginia Mason Medical Center, Wallace Rheumatic Study Center
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Altoona Center for Clinical ResearchFor profit1012005
Arsanis, Inc.For profit1112016
Coeur d Alene Arthritis ClinicAcademic/Hospital1012005
Denver Arthritis ClinicAcademic/Hospital1012005
Michigan State UniversityAcademic/Hospital1012005
PDL BioPharmaFor profit1112005
Stanford UniversityAcademic/Hospital1012005
Virginia Mason Medical CenterAcademic/Hospital1012005
Wallace Rheumatic Study CenterAcademic/Hospital1012005
9 organizations
Page 1 / 1